We are live on ! Find out more
AVEO

AVEO Pharmaceuticals

Delisted

AVEO was delisted on the 19th of January, 2023.

99 hedge funds and large institutions have $79.5M invested in AVEO Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 30 increasing their positions, 24 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

239% more call options, than puts

Call options by funds: $12.3M | Put options by funds: $3.64M

25% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 24

5% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 22

1.62% less ownership

Funds ownership: 41.23% → 39.61% (-1.6%)

2% less funds holding

Funds holding: 101 → 99 (-2)

26% less capital inflows, than outflows

Capital inflows: $16.9M | Capital outflows: $22.8M

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
99
Holders Change
-2
Holders Change %
-1.98%
% of All Funds
2.2%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
21
Increased
30
Reduced
24
Closed
22
Calls
$12.3​M
Puts
$3.64​M
Net Calls
+$8.68​M
Net Calls Change
-⁠$7.36​M

AVEO Hedge Fund Activity: Q4 2018 in Review

99 of the 4,507 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals (AVEO) for Q4 2018, worth a combined $79.5M — down 52% from $166M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of AVEO and 21 opened new positions — a net loss of 1 holder — while 24 trimmed existing stakes and 30 added.

The largest buyer was Granahan Investment Management, adding an estimated $5.12M. The largest seller was Polar Capital, exiting entirely with an estimated $13.6M sold.

  • 99 institutional investors held AVEO Pharmaceuticals (AVEO) as of Q4 2018, down from 101 in Q3 2018.
  • Funds reported $79.5M of AVEO Pharmaceuticals stock for Q4 2018, down 52% quarter-over-quarter.
  • 21 funds opened new AVEO Pharmaceuticals positions in Q4 2018 and 22 closed out, a net change of -1 holder.
  • The largest AVEO Pharmaceuticals buyer in Q4 2018 was Granahan Investment Management, an estimated $5.12M added.
  • The largest AVEO Pharmaceuticals seller in Q4 2018 was Polar Capital, an estimated $13.6M sold.

Based on aggregated 13F filings for Q4 2018.